Press Releases

California-based Notable announced that it has entered a partnership with the MDS Foundation, which is dedicated to providing insight to families on future clinical trials for myelodysplastic syndrome (MDS). Notable will offer a grant to support the MDS Foundation’s education...

Geneius Biotechnology is developing T cells as a quasi-personalized, off-the-shelf, therapy and preventive measure against COVID-19. The assumption is that by increasing the number of antigen-specific T cells in the body, the patient’s immune system can overwhelm the SARS-CoV-2...

Moderna, Inc., a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, and Lonza Ltd. announced a 10-year strategic collaboration agreement to enable larger scale manufacture of...

FUJIFILM Diosynth Biotechnologies, a world leading biologics-Contract Development and Manufacturing Organization (CDMO), announced that it will reserve manufacturing capacity for a future COVID-19 therapy for the COVID-19 Therapeutics Accelerator. The Therapeutics Accelerator is an initiative launched by the Bill...

WuXi Biologics, a global company with leading open-access biologics technology platforms, announced that its robotic aseptic filling isolator facility (DP4) has successfully completed the filling of two batches of pre-filled syringes (PFS). Using Vanrx SA25 to fill the two batches,...

Hardy Diagnostics, a medical device manufacturer based in Santa Maria, California, announced FDA EUA approval on April 24th for a new in vitro diagnostic medical device: Anti-SARS-CoV-2 Rapid Test (Cat. No. RTA0203). This immunoassay is intended for qualitative detection and...

ProteoGenix, a global leader in antibody production, is pleased to announce the first Human Immune COVID-19 library for the fast discovery of potent antibodies against SARS-CoV-2. "Highly sensitive and specific antibodies are critical for the development of diagnostics, therapeutics, and...